2. Academic Validation
  3. Arenobufagin Induces Apoptotic Cell Death in Human Non-Small-Cell Lung Cancer Cells via the Noxa-Related Pathway

Arenobufagin Induces Apoptotic Cell Death in Human Non-Small-Cell Lung Cancer Cells via the Noxa-Related Pathway

  • Molecules. 2017 Sep 11;22(9):1525. doi: 10.3390/molecules22091525.
Liang Ma 1,  Yindi Zhu 2,  Sheng Fang 3,  Hongyan Long 4,  Xiang Liu 5,  Zi Liu 6
Affiliations

Affiliations

  • 1 Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, Anhui, China. alexingma@163.com.
  • 2 Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, Anhui, China. zhuyindi0805@163.com.
  • 3 Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, Anhui, China. fngseng12345@163.com.
  • 4 Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, Anhui, China. longhongyan1995@163.com.
  • 5 Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, Anhui, China. liuxiang@ahut.edu.cn.
  • 6 Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan 243002, Anhui, China. tarring126@126.com.
PMID: 28892004 DOI: 10.3390/molecules22091525
Abstract

Arenobufagin, an active component isolated from the traditional Chinese medicine Chan Su, exhibits Anticancer influences in several human malignancies. However, the effects and action mechanisms of arenobufagin on non-small-cell lung Cancer (NSCLC) are still unknown. In this study, we reported that arenobufagin acted through activation of Noxa-related pathways and promoted apoptotic cell death in human NSCLC cells. Our results revealed that arenobufagin-induced Apoptosis was caspase-dependent, as evidenced by the fact that caspase-9, Caspase-3 and poly (ADP-ribose) polymerase (PARP) were cleaved, and pretreatment with a pan-caspase inhibitor Z-VAD-FMK inhibited the pro-apoptosis effect of arenobufagin. Mechanistically, we further found that arenobufagin rapidly upregulated the expression of the pro-apoptosis protein Noxa, and abrogated the anti-apoptosis protein Mcl-1, a major binding partner of Noxa in the cell. More importantly, the knockdown of Noxa greatly blocked arenobufagin-induced cell death, highlighting the contribution of this protein in the anti-NSCLC effects of arenobufagin. Interestingly, arenobufagin also increased the expression of p53, a direct transcriptional activator for the upregulation of the Noxa protein. Taken together, our results suggest that arenobufagin is a potential anti-NSCLC agent that triggers apoptotic cell death in NSCLC cells through interfering with the Noxa-related pathway.

Keywords

Mcl-1; Noxa; arenobufagin; non-small-cell lung cancer; p53.

Figures
Products